The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas

Seminars in Oncology

Volumn 40, Issue 1, 2013, Pages 100-108

  Smith, James ^a   Reidy Lagunes, Diane ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; HEPATOBILIARY SYSTEM CANCER; HUMAN; METASTASIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE;

CARCINOMA, NEUROENDOCRINE; COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UROGENITAL NEOPLASMS;

EID: 84873351920     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.11.011     Document Type: Article

References (78)

1. G.J. Gardner, D. Reidy-Lagunes, P.A. Gehrig Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document Gynecol Oncol 122 2011 190 198
2. C. Moertel, L. Kvols, M. O'Connell, J. Rubin Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 1991 227 232
3. G. Rindi, F. Inzani, E. Solcia Pathology of gastrointestinal disorders Endocrinol Metab Clin North Am 39 2010 713 727
4. C.R. Ferrone, L.H. Tang, J. Tomlinson Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25 2007 5609 5615
5. S. Van Eeden, P.F. Quaedvlieg, B.G. Taal, G.J. Offerhaus, C.B. Lamers, M.L. Van Velthuysen Classification of low-grade neuroendocrine tumors of midgut and unknown origin Hum Pathol 33 2002 1126 1132
6. J.R. Strosberg, A. Cheema, J. Weber, G. Han, D. Coppola, L.K. Kvols Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors J Clin Oncol 29 2011 3044 3049
7. A.I. Vinik, E.A. Woltering, R.R. Warner NANETS consensus guidelines for the diagnosis of neuroendocrine tumor Pancreas 39 2010 713 734
8. S. Yachida, E. Vakiani, C.M. White Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors Am J Surg Pathol 36 2012 173 184
9. G. Rindi, M. Falconi, C. Klersy TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study J Natl Cancer Inst 104 2012 764 777
10. D.S. Klimstra, I.R. Modlin, D. Coppola, R.V. Lloyd, S. Suster The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems Pancreas 39 2010 707 712
11. G. Rindi, G. Kloppel, A. Couvelard TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system Virchows Arch 451 2007 757 762
12. F. Bosman, F. Carneiro, R. Hruban, N. Theise WHO classification of tumours of the digestive system 2010 IARC Press Lyon, France
13. C.S. Cho, D.M. Labow, L. Tang Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms Cancer 113 2008 126 134
14. B.N. Fahy, L.H. Tang, D. Klimstra Carcinoid of the rectum risk stratification (CaRRS): a strategy for preoperative outcome assessment Ann Surg Oncol 14 2007 396 404
15. S.N. Hochwald, S. Zee, K.C. Conlon Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups J Clin Oncol 20 2002 2633 2642
16. J.R. Strosberg, D. Coppola, D.S. Klimstra The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas Pancreas 39 2010 799 800
17. J. Shia, L.H. Tang, M.R. Weiser Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 32 2008 719 731
18. J.C. Yao, M. Hassan, A. Phan One hundred years after " carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 2008 3063 3072
19. B. Brenner, M.A. Shah, M. Gonen, D.S. Klimstra, J. Shia, D.P. Kelsen Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases Br J Cancer 90 2004 1720 1726
20. P.E. Bernick, D.S. Klimstra, J. Shia Neuroendocrine carcinomas of the colon and rectum Dis Colon Rectum 47 2004 163 169
21. J. Strosberg, A. Nasir, D. Coppola, M. Wick, L. Kvols Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors Hum Pathol 40 2009 1262 1268
22. AJCC Cancer Staging Manual 2010 Springer Chicago, IL
23. S.X. Jiang, T. Mikami, A. Umezawa, M. Saegusa, T. Kameya, I. Okayasu Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity Am J Surg Pathol 30 2006 945 953
24. E.D. Staren, V.E. Gould, W.H. Warren, N.L. Wool, S. Bines, J. Baker Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation Surgery 104 1988 1080 1089
25. F. Casas, F. Ferrer, B. Farrus, J. Casals, A. Biete Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis Cancer 80 1997 1366 1372
26. T. Lad, S. Piantadosi, P. Thomas, D. Payne, J. Ruckdeschel, G. Giaccone A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy Chest 106 6 Suppl 1994 320S 323S
27. M. Takada, M. Fukuoka, M. Kawahara Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104 J Clin Oncol 20 2002 3054 3060
28. I. Oze, K. Hotta, K. Kiura, N. Ochi, N. Takigawa, Y. Fujiwara Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results PloS One 4 2009 e7835
29. K. Noda, Y. Nishiwaki, M. Kawahara Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 2002 85 91
30. P.N. Lara Jr, R. Natale, J. Crowley Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 J Clin Oncol 27 2009 2530 2535
31. L.B. Saltz, J.V. Cox, C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group N Engl J Med 343 2000 905 914
32. P.C. Thuss-Patience, A. Kretzschmar, D. Bichev Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Eur J Cancer 47 2011 2306 2314
33. E. Mitry, E. Baudin, M. Ducreux Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin Br J Cancer 81 1999 1351 1355
34. S. Iwasa, C. Morizane, T. Okusaka Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas Jpn J Clin Oncol 40 2010 313 318
35. J.D. Hainsworth, D.R. Spigel, S. Litchy, F.A. Greco Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study J Clin Oncol 24 2006 3548 3554
36. J. von Pawel, J.H. Schiller, F.A. Shepherd Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 1999 658 667
37. M.E. O'Brien, T.E. Ciuleanu, H. Tsekov Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer J Clin Oncol 24 2006 5441 5447
38. J.F. Smyth, I.E. Smith, C. Sessa Activity of docetaxel (Taxotere) in small cell lung cancer The Early Clinical Trials Group of the EORTC Eur J Cancer 30A 1994 1058 1060
39. E.F. Smit, E. Fokkema, B. Biesma, H.J. Groen, W. Snoek, P.E. Postmus A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer Br J Cancer 77 1998 347 351
40. G.A. Masters, L. Declerck, C. Blanke Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597 J Clin Oncol 21 2003 1550 1555
41. K. Furuse, K. Kubota, M. Kawahara Phase II study of vinorelbine in heavily previously treated small cell lung cancer Japan Lung Cancer Vinorelbine Study Group Oncology 53 1996 169 172
42. S. Onoda, N. Masuda, T. Seto Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301 J Clin Oncol 24 2006 5448 5453
43. I. Gounaris, J. Rahamim, S. Shivasankar, S. Earl, B. Lyons, D. Yiannakis Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma Anticancer Drugs 18 2007 1227 1230
44. D.P. Lindholm, B. Eriksson, D. Granberg Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma Med Oncol 29 2012 301 303
45. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. Epub 2011 Mar 31.
46. J. Albores-Saavedra, D. Gersell, C.B. Gilks Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute Arch Pathol Lab Med 121 1997 34 39
47. S.R. Moore, Y. Reinberg, G. Zhang Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy Urology 39 1992 411 416
48. E. Veras, M.T. Deavers, E.G. Silva, A. Malpica Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases Am J Surg Pathol 31 2007 774 782
49. N.A. Abrahams, C. Moran, A.O. Reyes, A. Siefker-Radtke, A.G. Ayala Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases Histopathology 46 2005 57 63
50. S. La Rosa, B. Bernasconi, D. Micello, G. Finzi, C. Capella Primary small cell neuroendocrine carcinoma of the kidney: morphological, immunohistochemical, ultrastructural, and cytogenetic study of a case and review of the literature Endocr Pathol 20 2009 24 34
51. L. Cheng, C.X. Pan, X.J. Yang Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients Cancer 101 2004 957 962
52. N.W. Choong, J.F. Quevedo, J.S. Kaur Small cell carcinoma of the urinary bladder The Mayo Clinic experience Cancer 103 2005 1172 1178
53. S.W. Lee, J.H. Nam, D.Y. Kim Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study Int J Gynecol Cancer 20 2010 411 416
54. A.N. Viswanathan, M.T. Deavers, A. Jhingran, P.T. Ramirez, C. Levenback, P.J. Eifel Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence Gynecol Oncol 93 2004 27 33
55. T.C. Chang, C.H. Lai, C.J. Tseng, S. Hsueh, K.G. Huang, H.H. Chou Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy Cancer 83 1998 712 718
56. O. Zivanovic, M.M. Leitao Jr, K.J. Park Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy Gynecol Oncol 112 2009 590 593
57. C.A. Moran, S. Suster Neuroendocrine carcinomas (carcinoid tumor) of the thymus A clinicopathologic analysis of 80 cases Am J Clin Pathol 114 2000 100 110
58. S.J. Shin, R.A. DeLellis, L. Ying, P.P. Rosen Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients Am J Surg Pathol 24 2000 1231 1238
59. T. Nagao, T.A. Gaffey, K.D. Olsen, H. Serizawa, J.E. Lewis Small cell carcinoma of the major salivary glands: clinicopathologic study with emphasis on cytokeratin 20 immunoreactivity and clinical outcome Am J Surg Pathol 28 2004 762 770
60. G.F. Hatoum, B. Patton, C. Takita Small cell carcinoma of the head and neck: the University of Miami experience Int J Radiat Oncol Biol Phys 74 2009 477 481
61. G. Renner Small cell carcinoma of the head and neck: a review Semin Oncol 34 2007 3 14
62. C.C. Li, B. Xu, M. Hirokawa Alterations of E-cadherin, alpha-catenin and beta-catenin expression in neuroendocrine tumors of the gastrointestinal tract Virchows Arch 440 2002 145 154
63. C.M. Rudin, R. Salgia, X. Wang Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103 J Clin Oncol 26 2008 870 876
64. G.K. Dy, A.A. Miller, S.J. Mandrekar A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann Onol 16 2005 1811 1816
65. K.J. Pandya, S. Dahlberg, M. Hidalgo A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500) J Thorac Oncol 2 2007 1036 1041
66. D.R. Spigel, J.D. Hainsworth, D.A. Yardley Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 28 2010 43 48
67. B.J. Gitlitz, J. Moon, B.S. Glisson Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial J Thorac Oncol 5 2010 1835 1840
68. S.S. Ramalingam, C.P. Belani, P.C. Mack Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097) J Thorac Oncol 5 2010 1279 1284
69. U.F. Pape, H. Jann, J. Muller-Nordhorn Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 2008 256 265
70. D.M. Maru, H. Khurana, A. Rashid Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus Am J Surg Pathol 32 2008 1404 1411
71. E. Solcia, G. Rindi, D. Paolotti Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors Yale J Biol Med 71 1998 285 290
72. H. Nassar, J. Albores-Saavedra, D.S. Klimstra High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases Am J Surg Pathol 29 2005 588 594
73. J. Albores-Saavedra, A. Hart, F. Chable-Montero, D.E. Henson Carcinoids and high-grade neuroendocrine carcinomas of the ampulla of vater: a comparative analysis of 139 cases from the surveillance, epidemiology, and end results program-A population based study Arch Pathol Lab Med 134 2010 1692 1696
74. K.M. Eltawil, B.I. Gustafsson, M. Kidd, I.M. Modlin Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy J Clin Gastroenterol 44 2010 687 695
75. N.T. Okita, K. Kato, D. Takahari Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma Gastric Cancer 14 2011 161 165
76. J.E. Oesterling, C.G. Hauzeur, G.M. Farrow Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients J Urol 147 1992 804 807
77. B. Helpap, G. Kloppel Neuroendocrine carcinomas of the prostate and urinary bladder: a diagnostic and therapeutic challenge Virchows Arch 440 2002 241 248
78. P.J. Hoskins, K.D. Swenerton, J.A. Pike Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy J Clin Oncol 21 2003 3495 3501